195 related articles for article (PubMed ID: 19509244)
21. Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways.
Janmaat ML; Kruyt FA; Rodriguez JA; Giaccone G
Clin Cancer Res; 2003 Jun; 9(6):2316-26. PubMed ID: 12796401
[TBL] [Abstract][Full Text] [Related]
22. mTOR co-targeting in cetuximab resistance in head and neck cancers harboring PIK3CA and RAS mutations.
Wang Z; Martin D; Molinolo AA; Patel V; Iglesias-Bartolome R; Degese MS; Vitale-Cross L; Chen Q; Gutkind JS
J Natl Cancer Inst; 2014 Sep; 106(9):. PubMed ID: 25099740
[TBL] [Abstract][Full Text] [Related]
23. Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTEN-intact glioblastoma cells.
Wang MY; Lu KV; Zhu S; Dia EQ; Vivanco I; Shackleford GM; Cavenee WK; Mellinghoff IK; Cloughesy TF; Sawyers CL; Mischel PS
Cancer Res; 2006 Aug; 66(16):7864-9. PubMed ID: 16912159
[TBL] [Abstract][Full Text] [Related]
24. mTOR inhibitors control the growth of EGFR mutant lung cancer even after acquiring resistance by HGF.
Ishikawa D; Takeuchi S; Nakagawa T; Sano T; Nakade J; Nanjo S; Yamada T; Ebi H; Zhao L; Yasumoto K; Nakamura T; Matsumoto K; Kagamu H; Yoshizawa H; Yano S
PLoS One; 2013; 8(5):e62104. PubMed ID: 23690929
[TBL] [Abstract][Full Text] [Related]
25. Novel targeted approaches to treating biliary tract cancer: the dual epidermal growth factor receptor and ErbB-2 tyrosine kinase inhibitor NVP-AEE788 is more efficient than the epidermal growth factor receptor inhibitors gefitinib and erlotinib.
Wiedmann M; Feisthammel J; Blüthner T; Tannapfel A; Kamenz T; Kluge A; Mössner J; Caca K
Anticancer Drugs; 2006 Aug; 17(7):783-95. PubMed ID: 16926628
[TBL] [Abstract][Full Text] [Related]
26. CCI-779 (Temsirolimus) exhibits increased anti-tumor activity in low EGFR expressing HNSCC cell lines and is effective in cells with acquired resistance to cisplatin or cetuximab.
Niehr F; Weichert W; Stenzinger A; Budach V; Tinhofer I
J Transl Med; 2015 Apr; 13():106. PubMed ID: 25890004
[TBL] [Abstract][Full Text] [Related]
27. Combination of cetuximab and rapamycin enhances the therapeutic efficacy in hepatocellular carcinoma.
Geng J; Li X; Lang X; Qiao C; Hu M; Yang J; Feng J; Lv M
Technol Cancer Res Treat; 2014 Aug; 13(4):377-85. PubMed ID: 24325131
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of mTOR pathway by everolimus cooperates with EGFR inhibitors in human tumours sensitive and resistant to anti-EGFR drugs.
Bianco R; Garofalo S; Rosa R; Damiano V; Gelardi T; Daniele G; Marciano R; Ciardiello F; Tortora G
Br J Cancer; 2008 Mar; 98(5):923-30. PubMed ID: 18319715
[TBL] [Abstract][Full Text] [Related]
29. Targeting EGFR and PI3K pathways in ovarian cancer.
Glaysher S; Bolton LM; Johnson P; Atkey N; Dyson M; Torrance C; Cree IA
Br J Cancer; 2013 Oct; 109(7):1786-94. PubMed ID: 24022196
[TBL] [Abstract][Full Text] [Related]
30. EGFR targeting monoclonal antibody combines with an mTOR inhibitor and potentiates tumor inhibition by acting on complementary signaling hubs.
James R; Vishwakarma S; Chivukula IV; Basavaraj C; Melarkode R; Montero E; Nair P
Cancer Med; 2012 Oct; 1(2):114-27. PubMed ID: 23342262
[TBL] [Abstract][Full Text] [Related]
31. Targeting of active mTOR inhibits primary leukemia T cells and synergizes with cytotoxic drugs and signaling inhibitors.
Batista A; Barata JT; Raderschall E; Sallan SE; Carlesso N; Nadler LM; Cardoso AA
Exp Hematol; 2011 Apr; 39(4):457-472.e3. PubMed ID: 21277936
[TBL] [Abstract][Full Text] [Related]
32. Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition.
Sun SY; Rosenberg LM; Wang X; Zhou Z; Yue P; Fu H; Khuri FR
Cancer Res; 2005 Aug; 65(16):7052-8. PubMed ID: 16103051
[TBL] [Abstract][Full Text] [Related]
33. Combinatorial effects of lapatinib and rapamycin in triple-negative breast cancer cells.
Liu T; Yacoub R; Taliaferro-Smith LD; Sun SY; Graham TR; Dolan R; Lobo C; Tighiouart M; Yang L; Adams A; O'Regan RM
Mol Cancer Ther; 2011 Aug; 10(8):1460-9. PubMed ID: 21690228
[TBL] [Abstract][Full Text] [Related]
34. Epidermal growth factor receptor dynamics influences response to epidermal growth factor receptor targeted agents.
Jimeno A; Rubio-Viqueira B; Amador ML; Oppenheimer D; Bouraoud N; Kulesza P; Sebastiani V; Maitra A; Hidalgo M
Cancer Res; 2005 Apr; 65(8):3003-10. PubMed ID: 15833824
[TBL] [Abstract][Full Text] [Related]
35. Cotargeting of epidermal growth factor receptor and PI3K overcomes PI3K-Akt oncogenic dependence in pancreatic ductal adenocarcinoma.
Wong MH; Xue A; Julovi SM; Pavlakis N; Samra JS; Hugh TJ; Gill AJ; Peters L; Baxter RC; Smith RC
Clin Cancer Res; 2014 Aug; 20(15):4047-58. PubMed ID: 24895459
[TBL] [Abstract][Full Text] [Related]
36. Exogenous Restoration of TUSC2 Expression Induces Responsiveness to Erlotinib in Wildtype Epidermal Growth Factor Receptor (EGFR) Lung Cancer Cells through Context Specific Pathways Resulting in Enhanced Therapeutic Efficacy.
Dai B; Yan S; Lara-Guerra H; Kawashima H; Sakai R; Jayachandran G; Majidi M; Mehran R; Wang J; Bekele BN; Baladandayuthapani V; Yoo SY; Wang Y; Ying J; Meng F; Ji L; Roth JA
PLoS One; 2015; 10(6):e0123967. PubMed ID: 26053020
[TBL] [Abstract][Full Text] [Related]
37. Synergic antiproliferative and antiangiogenic effects of EGFR and mTor inhibitors on pancreatic cancer cells.
Azzariti A; Porcelli L; Gatti G; Nicolin A; Paradiso A
Biochem Pharmacol; 2008 Mar; 75(5):1035-44. PubMed ID: 18191814
[TBL] [Abstract][Full Text] [Related]
38. Targeting TORC1/2 enhances sensitivity to EGFR inhibitors in head and neck cancer preclinical models.
Cassell A; Freilino ML; Lee J; Barr S; Wang L; Panahandeh MC; Thomas SM; Grandis JR
Neoplasia; 2012 Nov; 14(11):1005-14. PubMed ID: 23226094
[TBL] [Abstract][Full Text] [Related]
39. mTOR inhibition induces EGFR feedback activation in association with its resistance to human pancreatic cancer.
Wei F; Zhang Y; Geng L; Zhang P; Wang G; Liu Y
Int J Mol Sci; 2015 Feb; 16(2):3267-82. PubMed ID: 25654224
[TBL] [Abstract][Full Text] [Related]
40. Everolimus synergizes with gefitinib in non-small-cell lung cancer cell lines resistant to epidermal growth factor receptor tyrosine kinase inhibitors.
Dong S; Zhang XC; Cheng H; Zhu JQ; Chen ZH; Zhang YF; Xie Z; Wu YL
Cancer Chemother Pharmacol; 2012 Nov; 70(5):707-16. PubMed ID: 22941374
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
